Endoceutics - Common Shares (MM) (ENCX)

Endoceutics, Inc., a biopharmaceutical company, engages in the research and development of hormone therapies. The company develops acolbifene, for the treatment and prevention of breast cancer; and dehydroepiandrosterone (DHEA), for medical indications affecting postmenopausal women and ageing men. ... Endoceutics, Inc., a biopharmaceutical company, engages in the research and development of hormone therapies. The company develops acolbifene, for the treatment and prevention of breast cancer; and dehydroepiandrosterone (DHEA), for medical indications affecting postmenopausal women and ageing men. It also develops acolbifene and DHEA in combination as an alternative to traditional hormone replacement therapy for the treatment of vaginal atrophy, muscle mass and strength loss, type II diabetes, obesity, high cholesterol, and bone loss. In addition, the company develops preclinical compounds and non-estrogen based therapies for the treatment of endocrine-related disorders, including acne, oily skin, male pattern baldness, prostate cancer, and benign prostate enlargement; and a preclinical-stage selective androgen receptor modulator for the treatment of muscle atrophy and bone loss in aging men and women. Further, it provides bioanalytical services for analyzing serum and tissue samples, clinical studies, and intracrinology studies. The company was founded in 2006 and is based in Quebec, Canada. EndoCeutics, Inc. operates as a subsidiary of EndoResearch, Inc. 詳細を表示